Navigation Links
Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
Date:5/27/2009

VANCOUVER, May 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.

"The rapid adoption of the TAXUS Express Atom Stent has confirmed the need for this type of stenting option in the treatment of small-vessel coronary artery disease," said Mark Turco, M.D., F.A.C.C., F.S.C.A.I., Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "The TAXUS Liberte Atom Stent provides clear design and deliverability advantages. Additionally, in the TAXUS Atlas Small Vessel clinical trial, the TAXUS Liberte Atom Stent yielded a two-year target lesion revascularization rate that was 60 percent less than the TAXUS Express Atom Stent. I am pleased to be able to offer this option to my patients."

Data from numerous clinical studies have shown that an estimated 10 percent of patients undergoing percutaneous coronary interventions have small vessels ((less than)2.5 mm). Until recently, many physicians were inclined to implant bare-metal stents in these patients since they were the only approved stenting option for small vessels. Last year's launch of the TAXUS Expre
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 Diasome Pharmaceuticals, Inc. ... SDG, Inc., that a United States patent has recently ... therapy. , Entitled “Lipid Construct for Delivery ... of matter claims related to the use of Diasome’s ... enabling injected insulin to more effectively reach the liver’s ...
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... , leadership consulting and culture shaping ... the firm to lead its global Healthcare and Life Sciences ... and Life Sciences, Mitchell will lead a team of more ... Europe and Asia ...
(Date:3/30/2015)... , March 30, 2015 /CNW/ - A new national ... the salaries and demographic profiles of new graduates entering ... Door – Building Careers for New Grads in Biotech," ... Research-Based Pharmaceutical Companies (Rx&D) and features data collected ... Focus wage subsidy program from 2013 to 2015. ...
(Date:3/30/2015)... FLORHAM PARK, N.J. , March 30, 2015 ... antagonist (PAMORA) under development by Shionogi & Co., ... a phase III study (COMPOSE I) for the ... with chronic non-cancer pain receiving opioid therapy. Study ... once daily) statistically significantly improved the frequency of ...
Breaking Biology Technology:Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... ... Fuels to Power Cars, PHILADELPHIA, Nov. 12 The ... chemical,engineers, is holding its Centennial Annual Meeting in Philadelphia from,Nov. ... leaders, engineers,and students are expected. In celebration of the 100th ...
... Network to Meet Market Demands for Global ... plc (NASDAQ: ICLR;,ISIN:IE0005711209), a global provider of ... medical device industries, today,announced the opening of ... The purpose-built, 15,000 sq ft facility expands ...
... Genomma Lab Internacional, S.A.B.,de C.V. (BMV: LAB) ... pharmaceuticals and personal care products company,announced today that ... removal chain,"Neoskin," which has recently been the subject ... March 2008, it divested all its,shares of Global ...
Cached Biology Technology:Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial 2ICON Opens Full Service Central Laboratory in India 2
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... The humble papaya is gaining credibility in Western medicine ... generations. University of Florida researcher Nam Dang, M.D., ... anticancer effect against a broad range of lab-grown tumors, ... pancreas. The researchers used an extract made from dried ...
... Technical Research Centre of Finland will establish a Centre of ... the water sector is being gathered into one centre. The ... the water sector in Finland and to create new business ... research centre will be known as the Centre of Water ...
... - For decades, the traditional practice in animal testing ... has shown that adding as few as two controlled ... costly false positives, the number of animals needed for ... Joseph Garner, a Purdue assistant professor of animal sciences, ...
Cached Biology News:Papaya extract thwarts growth of cancer cells in lab tests 2Finland to get a Center of Water Efficiency Excellence 2Intentional variation increases result validity in mouse testing 2Intentional variation increases result validity in mouse testing 3
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
... Small Molecule Localization in Early Drug ... Get essential drug compound localization ... spectrometry. Protein Discoverys imaging mass spectrometry service ... them with histological images so you can ...
... LC Sciences provides a comprehensive kinase ... kinase substrate (PKS) peptide microarrays synthesized ... scale kinase profiling, quantitative measurement of ... research. This comprehensive service includes preparation ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: